Beranda › Kanker Paru Non-Sel Kecil › Texas › Dallas
Uji klinis Kanker Paru Non-Sel Kecil di Dallas, TX
52 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Dallas (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Menerima pesertaFase 3
- Texas Oncology - DFW ( Site 8103), Dallas
- UT Southwestern Medical Center ( Site 0190), Dallas
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- UT Southwest Simmons Cancer Center, Dallas
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Menerima pesertaFase 1
- Exelixis Clinical Site #89, Dallas
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Menerima pesertaFase 1
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Menerima pesertaFase 3
- Texas Oncology Dallas, Dallas
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- dan 2 lainnya
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- dan 2 lainnya
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Menerima pesertaFase 1
- Research Site, Dallas
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Parkland Health and Hospital System, Dallas
- Texas Oncology DFW, Dallas
- UT Southwestern Medical Center, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Menerima pesertaFase 1/2
- Baylor, Scott and White Research Institute, Dallas
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 1
- UT Southwestern Medical Center at Dallas, Dallas
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Menerima pesertaFase 2
- Texas Oncology - Dallas - Worth Street /ID# 278947, Dallas
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Menerima pesertaFase 3
- Texas Oncology Sammons Cancer Center, Dallas
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Menerima pesertaFase 3
- Clinical Study Site, Dallas
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Menerima pesertaFase 1
- NEXT - Dallas, Dallas
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Menerima pesertaFase 2/3
- Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Menerima pesertaStudi observasional
- UT Southwestern Medical Center, Dallas
A Study of KK2269 in Adult Participants With Solid Tumors
Menerima pesertaFase 1
- The University of Texas Southwestern Medical Center, Dallas
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Menerima pesertaFase 1
- Mary Crowley Cancer Research, Dallas
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Menerima pesertaFase 1/2
- Mary Crowley Cancer Research, Dallas
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- The University of Texas Southwestern Medical Center at Dallas, Dallas
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Menerima pesertaFase 1
- Ut Southwestern, Dallas
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Menerima pesertaFase 3
- Texas Oncology, Dallas
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Menerima pesertaFase 2
- Baylor Charles A. Sammons Cancer Center, Dallas
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Menerima pesertaFase 1/2
- Texas Oncology - DFW, Dallas
A Study of DM005 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Sarah Cannon Research Institute at Mary Crowley, Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Menerima pesertaFase 1/2
- Mary Crowley Cancer Research, Dallas
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Menerima pesertaFase 1
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- dan 2 lainnya
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Menerima pesertaFase 2
- Texas Oncology - DFW, Dallas
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
Menerima pesertaFase awal 1
- University of Texas Southwestern Medical Center, Dallas
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Menerima pesertaFase 3
- Old Parkland Hospital Hematology Oncology Clinic, Dallas
- UT Southwestern Medical Center, Dallas
Study of XB010 in Subjects With Solid Tumors
Menerima pesertaFase 1
- Baylor University Medical Center, Dallas
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Menerima pesertaFase 1
- NEXT Texas LLC - Dallas, Dallas
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Menerima pesertaFase 1
- UT Southwestern Simmons Cancer Center, Dallas
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Menerima pesertaFase 1
- University of Texas Southwestern Medical Center /ID# 251974, Dallas
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Menerima pesertaFase 1
- Sarah Cannon Research Institute at Mary Crowley, Dallas
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Menerima pesertaFase 1
- Sarah Cannon Research Institute at Mary Crowley, Dallas
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Menerima pesertaFase 1/2
- UT Southwestern Medical Center, Dallas
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Menerima pesertaFase 1/2
- Mary Crowley Cancer Research, Dallas
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Menerima pesertaFase 2
- UT Southwestern Medical Center, Dallas
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Menerima pesertaFase 2
- University of Texas Southwestern Medical Center, Dallas
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Menerima pesertaFase 3
- University of Texas Southwestern Medical Center, Dallas
A Study of VET3-TGI in Patients With Solid Tumors
Menerima pesertaFase 1
- Mary Crowley Cancer Research, Dallas
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1
- NEXT Dallas, Dallas
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Menerima pesertaFase 1/2
- Research Site, Dallas
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Menerima pesertaFase 1/2
- NEXT Oncology - Dallas, Dallas
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Menerima pesertaFase 1/2
- NEXT Oncology Dallas, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Menerima pesertaFase 1
- Dren Investigational Site, Dallas
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1/2
- Research Site 120, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Dallas
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Baylor Scott and White Research Institute, Dallas
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY120 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH56 studi
- Washington, DC55 studi
Studi lain di Dallas
- Kanker Payudara55 studi
- Kanker Metastatik42 studi
- Gagal Jantung42 studi
- Kanker (semua jenis)37 studi
- Kanker Prostat36 studi
- Kanker Kolorektal33 studi
- Obesitas30 studi
- Kanker Ovarium28 studi
- Kanker Kandung Kemih27 studi
- Kanker Paru27 studi
- Kanker Endometrium24 studi
- Penyakit Kardiovaskular23 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.